# Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)

> **NCT04306471** · PHASE4 · UNKNOWN · sponsor: **Leonardo Clavijo** · enrollment: 32 (estimated)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **DRUG:** Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
- **OTHER:** Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months

## Key facts

- **NCT ID:** NCT04306471
- **Lead sponsor:** Leonardo Clavijo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-24
- **Primary completion:** 2021-02-04
- **Final completion:** 2022-02-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2020-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04306471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04306471, "Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04306471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*